Research programme: cannabinoid therapeutics - CannaPharmaRx

Drug Profile

Research programme: cannabinoid therapeutics - CannaPharmaRx

Latest Information Update: 17 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CannaPharmaRx
  • Class Cannabinoids; Small molecules
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Cancer; Eye-Disorders; Gastrointestinal disorders; Infections; Inflammation; Metabolic disorders; Neurodegenerative disorders; Pain

Most Recent Events

  • 30 Nov 2015 Research programme: small molecule therapeutics - CannaPharmaRx is available for licensing as of 30 Nov 2015.
  • 30 Nov 2015 Early research in Cancer in USA (unspecified route)
  • 30 Nov 2015 Early research in Eye disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top